The outlook of companies tied to blockbuster drugs like Viagra presents a challenging investment picture. While the initial rise of copyright, fueled by Viagra's extraordinary popularity, generated substantial returns, the loss of exclusivity in key markets has introduced substantial volatility. Investors are now assessing the effect of generic com